Cancer Genetics

Historical Context & Motivation

The recognition that cancer has a genetic basis fundamentally transformed oncology from a discipline focused on gross tissue pathology to one grounded in molecular biology. Before the mid-twentieth century, clinicians observed that certain cancers clustered in families and that chemical carcinogens could induce tumors, yet the mechanistic link between DNA alterations and neoplastic transformation remained elusive. The discovery of oncogenes and tumor suppressor genes provided the conceptual framework that unified hereditary cancer syndromes, sporadic malignancies, and environmentally induced carcinogenesis under a single genetic paradigm. Understanding this history is essential for interpreting modern cancer therapeutics and the rationale behind genetic screening programs.

The central question that cancer genetics addresses is deceptively simple: how do normal cells acquire the capacity for uncontrolled proliferation, evasion of apoptosis, and metastatic dissemination? The answer lies in the progressive accumulation of genetic and epigenetic alterations that disrupt the tightly regulated balance between cell growth and cell death. Mastering these concepts is high-yield for USMLE Step 1, as questions frequently integrate molecular genetics with clinical cancer syndromes and pharmacologic intervention.

Core Principles & Definitions

Cancer genetics rests on a set of foundational concepts that distinguish it from classical Mendelian inheritance. Unlike single-gene disorders where one mutation is sufficient to produce a phenotype, carcinogenesis typically requires the sequential accumulation of multiple genetic hits across distinct regulatory pathways. This multi-step model of carcinogenesis explains why cancer incidence rises exponentially with age and why inherited cancer syndromes — which provide a "head start" with one constitutional mutation — present at younger ages than their sporadic counterparts.

Visual Explanation — Multi-Step Carcinogenesis

The Vogelstein model of colorectal carcinogenesis is one of the most thoroughly characterized examples of multi-step tumorigenesis and serves as a paradigm for understanding cancer genetics across organ systems. The sequence begins with biallelic loss of the APC tumor suppressor on chromosome 5q, which normally functions within the Wnt signaling pathway to promote degradation of β-catenin. When APC is lost, β-catenin accumulates in the nucleus and constitutively activates transcription of pro-proliferative genes, producing the initial hyperplastic lesion. Subsequent activating mutations in KRAS lock the RAS-MAPK signaling cascade in an "on" state, driving clonal expansion into a dysplastic adenoma. Progressive loss of SMAD4 and ultimately TP53 removes critical checkpoints governing TGF-β responsiveness and DNA damage response, enabling the transition to invasive carcinoma with metastatic potential.

Molecular Mechanisms of Oncogene Activation & Tumor Suppressor Inactivation

Mechanisms of Oncogene Activation

Proto-oncogenes can be converted to oncogenes through several distinct molecular mechanisms, each of which results in either overexpression or constitutive activation of the gene product. Point mutations represent the simplest mechanism, as exemplified by single amino acid substitutions in RAS family genes (codons 12, 13, or 61) that abolish GTPase activity and lock RAS in its GTP-bound active conformation. Gene amplification produces multiple copies of a proto-oncogene, generating supraphysiological levels of protein — this is the mechanism underlying HER2/neu (ERBB2) overexpression in approximately 20% of breast cancers, which forms the therapeutic target for trastuzumab.

Chromosomal translocation can activate oncogenes by two mechanisms. First, a translocation may place a proto-oncogene under control of a highly active promoter, as seen in Burkitt lymphoma where t(8;14) juxtaposes MYC with the immunoglobulin heavy chain promoter. Second, a translocation may generate a novel fusion protein with constitutive kinase activity, as in the t(9;22) Philadelphia chromosome producing BCR-ABL in chronic myelogenous leukemia (CML). The BCR-ABL fusion protein has constitutive tyrosine kinase activity and is the target of imatinib mesylate.

Mechanisms of Tumor Suppressor Inactivation

Tumor suppressor inactivation requires loss of function in both alleles, consistent with Knudson's two-hit model. The first hit is typically a point mutation or small deletion in one allele, while the second hit may occur through loss of heterozygosity (LOH) — a large chromosomal deletion, mitotic recombination, or whole-chromosome loss (monosomy) that eliminates the remaining wild-type allele. Alternatively, epigenetic silencing through promoter hypermethylation can functionally inactivate a tumor suppressor without altering its DNA sequence. This is commonly observed with MLH1 in sporadic microsatellite-unstable colorectal cancers.

The p53 Pathway — Guardian of the Genome

The TP53 gene on chromosome 17p13 encodes the p53 transcription factor, often called the "guardian of the genome." Under normal conditions, p53 protein levels are kept low by MDM2-mediated ubiquitination and proteasomal degradation. When DNA damage is detected, ATM/ATR kinases phosphorylate p53, preventing its degradation and allowing it to accumulate. Activated p53 then initiates three critical responses: cell cycle arrest at G₁/S via transcriptional activation of p21 (a CDK inhibitor), DNA repair through upregulation of repair enzymes, or apoptosis via induction of BAX if damage is irreparable. Loss of p53 function is the single most common genetic alteration in human cancers, occurring in over 50% of malignancies.

Hereditary Cancer Syndromes & Classification

Hereditary cancer syndromes account for approximately 5–10% of all cancers but provide invaluable insight into the genetic basis of malignancy. Patients with these syndromes inherit one defective allele in the germline, requiring only a single somatic "second hit" to initiate tumorigenesis. This explains the hallmark features of hereditary cancer: earlier age of onset, bilateral or multifocal tumors, and autosomal dominant inheritance pattern within families. The following table summarizes the highest-yield cancer syndromes tested on USMLE Step 1.

Worked Example — Clinical Vignette Analysis

The following worked example demonstrates how to systematically approach a USMLE-style question integrating cancer genetics with clinical presentation and molecular biology.

Oncogenes vs. Tumor Suppressor Genes — A Comparative Framework

One of the most frequently tested distinctions in cancer genetics is the contrast between oncogenes and tumor suppressor genes. These two categories of cancer-associated genes differ in their normal function, mechanism of activation, inheritance pattern at the cellular level, and therapeutic implications. The following table provides a comprehensive side-by-side comparison.

Connection to Advanced Theory — Genomic Instability & Targeted Therapy

Beyond the classical oncogene/tumor suppressor framework, modern cancer genetics has expanded to encompass concepts of genomic instability, epigenetic reprogramming, and synthetic lethality as a therapeutic strategy. These concepts represent the frontier of cancer genetics and are increasingly appearing in updated USMLE content.

The concept of synthetic lethality deserves special attention as it represents a paradigm shift in treating tumors driven by loss-of-function mutations, which are inherently difficult to target pharmacologically. In BRCA1/2-mutant cells, homologous recombination repair is defective. These cells rely on alternative repair pathways such as base excision repair (mediated by PARP enzymes) to maintain viability. PARP inhibitors block this backup pathway, creating a situation where neither repair pathway functions — a synthetic lethal interaction that selectively kills tumor cells while sparing normal cells with intact BRCA function. This principle extends beyond BRCA and is being explored for other caretaker gene deficiencies.

Practice Problems

Cancer Genetics — Comprehensive Review